Physician profile
John A Grant
NPI 1700945342
$1,932.96
in general payments reported to CMS, 2019-2025
9 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $135 · 2021: $144 · 2022: $205 · 2023: $336 · 2024: $611 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $767.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $425.87 | 2019-2025 | Fasenra, Tezspire |
| Shire North American Group INC | $212.03 | 2019 | |
| Genentech USA, INC. | $147.50 | 2024 | Xolair |
| Amgen INC. | $102.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.37 | 2023 | Cuvitru |
| Blueprint Medicines Corporation | $97.35 | 2024 | Ayvakit |
| Glaxosmithkline, LLC. | $56.65 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $22.61 | 2024 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.